- $55.42m
- -$120.89m
- 11
- 53
- 40
- 26
Annual balance sheet for Adicet Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 94.6 | 278 | 258 | 160 | 176 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2.73 | 0.214 | 0.435 | 0 | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 100 | 282 | 261 | 162 | 180 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 25.9 | 35 | 49 | 44.2 | 36.8 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 154 | 339 | 331 | 207 | 220 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 22.5 | 16.3 | 19.7 | 19.3 | 19.4 |
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 44 | 35.8 | 38.4 | 37.1 | 33.6 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 110 | 303 | 292 | 170 | 187 |
Total Liabilities & Shareholders' Equity | 154 | 339 | 331 | 207 | 220 |
Total Common Shares Outstanding |